GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Cyclically Adjusted PB Ratio

Revance Therapeutics (Revance Therapeutics) Cyclically Adjusted PB Ratio : 0.50 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Revance Therapeutics's current share price is $2.70. Revance Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $5.39. Revance Therapeutics's Cyclically Adjusted PB Ratio for today is 0.50.

The historical rank and industry rank for Revance Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

RVNC' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.5   Med: 4.35   Max: 6.89
Current: 0.5

During the past years, Revance Therapeutics's highest Cyclically Adjusted PB Ratio was 6.89. The lowest was 0.50. And the median was 4.35.

RVNC's Cyclically Adjusted PB Ratio is ranked better than
73.68% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs RVNC: 0.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Revance Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $-0.945. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.39 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Revance Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Revance Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Cyclically Adjusted PB Ratio Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.49 1.61

Revance Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 4.90 2.20 1.61 0.91

Competitive Comparison of Revance Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Revance Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Cyclically Adjusted PB Ratio falls into.



Revance Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Revance Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.70/5.39
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revance Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Revance Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.945/131.7762*131.7762
=-0.945

Current CPI (Mar. 2024) = 131.7762.

Revance Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 8.449 100.560 11.072
201409 7.923 100.428 10.396
201412 7.418 99.070 9.867
201503 6.826 99.621 9.029
201506 6.216 100.684 8.136
201509 5.855 100.392 7.685
201512 8.952 99.792 11.821
201603 8.319 100.470 10.911
201606 7.576 101.688 9.818
201609 7.039 101.861 9.106
201612 6.181 101.863 7.996
201703 5.930 102.862 7.597
201706 5.241 103.349 6.683
201709 4.592 104.136 5.811
201712 7.362 104.011 9.327
201803 6.440 105.290 8.060
201806 5.684 106.317 7.045
201809 4.923 106.507 6.091
201812 3.938 105.998 4.896
201903 5.025 107.251 6.174
201906 4.275 108.070 5.213
201909 3.430 108.329 4.172
201912 4.305 108.420 5.232
202003 5.408 108.902 6.544
202006 4.462 108.767 5.406
202009 5.599 109.815 6.719
202012 5.410 109.897 6.487
202103 3.420 111.754 4.033
202106 2.594 114.631 2.982
202109 1.673 115.734 1.905
202112 0.957 117.630 1.072
202203 0.356 121.301 0.387
202206 -0.036 125.017 -0.038
202209 1.771 125.227 1.864
202212 0.153 125.222 0.161
202303 -0.317 127.348 -0.328
202306 0.305 128.729 0.312
202309 -1.209 129.860 -1.227
202312 -1.724 129.419 -1.755
202403 -0.945 131.776 -0.945

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Revance Therapeutics  (NAS:RVNC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Revance Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (Revance Therapeutics) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080